Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REFILE-TREASURIES-U.S. yields little changed on caution about stimulus package

Tue, 26th Jan 2021 15:48

(Fixes typo in U.S. Treasury 10-year yield to 1.03% in 7th
paragraph)
By Gertrude Chavez-Dreyfuss
NEW YORK, Jan 26 (Reuters) - U.S. Treasury yields were
little changed to slightly higher in choppy trading on Tuesday,
after hitting three-week lows on the long end of the curve, as
investors remained cautious in the near term about the size of a
proposed U.S. stimulus package as well as the slow global
roll-out of coronavirus vaccines.
The U.S yield curve steepened modestly after flattening on
Monday. The spread between U.S. two-year and 10-year yields
widened modestly to 91.50 basis points.
U.S. Senate Majority Leader Chuck Schumer said late on
Monday that he and his fellow Democrats may try to pass much of
President Joe Biden's $1.9 trillion coronavirus relief bill
using a process that would bypass a Republican filibuster and
could allow it to pass with a majority vote.
"We think ultimately it's going to be smaller than the $1.9
trillion," said Mike Chang, interest rates strategist at Citi in
New York. "We have penciled in around $600 billion-$1 trillion.
Timing is another issue, not just the size - how long it will
take to get the whole thing through."
In addition, there have been coronavirus vaccine delivery
problems globally, especially in Europe.
AstraZeneca, which developed its vaccine with Oxford
University, told the European Union that it could not meet
agreed supply targets by the end of March. Pfizer Inc
said there would be a temporary impact on shipments of its
vaccine in late January to early February.
In mid-morning trading, the U.S. benchmark 10-year yield
fell to 1.03%, from 1.04% late on Monday. It earlier
fell to 1.026%, its lowest level since Jan. 6.
U.S. 30-year yields slid to 1.7955% from
Monday's 1.799%, after earlier dropping to a three-week low of
1.786%.
U.S. 20-year bond yields also weakened to a
three-week trough and were last down at 1.59%.
On the front end of the curve, U.S. two-year yields slipped
to 0.121% from 0.127% on Monday.
Also on Tuesday, the Treasury auctions a record $61 billion
in 5-year notes after a solid 2-year debt sale on Monday.
"We believe there will be demand as the Treasury market has
had a firm tone in recent sessions," Justin Lederer, rates
strategist at Cantor Fitzgerald, said in a research note.
"We, however, would not be surprised by a small back-up
leading into 1 pm (bid deadline) and/or small tail as market
participants are cautious at the current yield levels, as the
sector is trading at its richest levels since early January and
12 basis points lower than its high yield print a few weeks
ago," he added.
Ahead of the auction, U.S. five-year note yields were little
changed at 0.4119%.

January 26 Tuesday 10:28AM New York / 1528 GMT
Price Current Net
Yield % Change
(bps)
Three-month bills 0.08 0.0811 0.000
Six-month bills 0.085 0.0862 -0.003
Two-year note 100-1/256 0.123 -0.004
Three-year note 99-214/256 0.1805 0.000
Five-year note 99-210/256 0.4119 0.002
Seven-year note 99-80/256 0.727 0.002
10-year note 98-116/256 1.0414 0.001
20-year bond 96-12/256 1.6089 0.005
30-year bond 95-236/256 1.8024 0.003

DOLLAR SWAP SPREADS
Last (bps) Net
Change
(bps)
U.S. 2-year dollar swap 7.50 -0.25
spread
U.S. 3-year dollar swap 8.25 0.25
spread
U.S. 5-year dollar swap 10.00 0.50
spread
U.S. 10-year dollar swap 3.25 0.25
spread
U.S. 30-year dollar swap -24.00 0.00
spread


(Reporting by Gertrude Chavez-Dreyfuss
Editing by Paul Simao)

More News
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.